



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 333/56, 207/02, 409/10, 413/10	A1	(11) International Publication Number: WO 97/34888 (43) International Publication Date: 25 September 1997 (25.09.97)
(21) International Application Number: PCT/US96/03934 (22) International Filing Date: 20 March 1996 (20.03.96) (30) Priority Data: 60/013,674 19 March 1996 (19.03.96) US (60) Parent Application or Grant (63) Related by Continuation US 60/013,674 (CON) Filed on 19 March 1996 (19.03.96) (71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): JONES, Charles, David [US/US]; 223 East Brunswick Avenue, Indianapolis, IN 46227 (US). McGILL, John, McNeill, III [US/US]; 1120 Hasp Way, Lafayette, IN 47906 (US). (74) Agents: BOONE, David, E. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).		(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: SYNTHESIS OF 3-[4-(2-AMINOETHOXY)-BENZOYL]-2-ARYL-6-HYDROXY-BENZO[b]THIOPHENES		
(57) Abstract The present invention is directed to chemical processes for preparing 2-aryl-6-hydroxy-3-[4-(2-aminoethoxy)benzoyl]benzo[b]-thiophenes.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

SYNTHESIS OF 3-[4-(2-AMINOETHOXY)-
BENZOYL]-2-ARYL-6-HYDROXYBENZO[b]THIOPHENES

5

Background of the Invention

The present invention is directed to chemical processes for preparing 2-aryl-6-hydroxy-3-[4-(2-aminoethoxy)-benzoyl]benzo[b]thiophenes. The synthesis of aromatic ketones was reviewed by Gore in **Olah, Friedel-Crafts and Related Reactions**, Volume 3, Part 1, Chapter XXXI (1964). Generally, an acyl component and an aromatic substrate are reacted in the presence of a Lewis acid catalyst to produce the aromatic ketone. Suitable Lewis acid catalysts for this type of reaction include metal halides such as aluminum chloride, aluminum bromide, ferric chloride, and ferric bromide. See **Olah, Friedel-Crafts and Related Reactions**, Volume 1, Chapters II, III, and IV (1963).

The compounds prepared by the present processes were first described in U.S. Patent No. 4,133,814. This patent described a number of processes for preparing the compounds, including the reaction of 2-arylbenzo[b]thiophenes-3-carboxylic acids with alkyl phenyl ethers. This patent taught the use of phenacyl, halophenacyl, and alkyl protecting groups for the phenolic hydroxyl groups. The alkyl protecting groups were removed by treating the phenolic ethers with pyridine hydrochloride. This patent also taught that the phenolic methyl ethers could be cleaved without affecting the 3-aryloxy group by reacting with boron tribromide; however, the yield of the 3-aryloxy-substituted compound was low.

The process described in U.S. Patent No. 4,358,593 used particularly advantageous protecting groups for preparing 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-aminoethoxy)benzoyl]benzo[b]thiophenes. These advantageous protecting groups are acetyl, substituted acetyl, benzoyl, alkylsulfonyl, and arylsulfonyl groups. This patent taught the use of classical Friedel-Crafts catalysts in the acylation of the protected 2-

- 2 -

(4-hydroxyphenyl)-6-hydroxybenzo[b]thiophene, including metal halides such as aluminum chloride, aluminum bromide, zinc chloride, boron trifluoride, boron tribromide, titanium tetrachloride, titanium tetrabromide, stannic chloride, stannic bromide, bismuth trichloride, and ferric chloride. Subsequent to acylation, the protecting group was generally removed under basic conditions.

A particularly useful compound from this series of 2-aryl-3-[4-(2-aminoethoxy)benzoyl]benzo[b]thiophenes is 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene. This compound, as well as methods for its preparation, was first described in U.S. Patent No. 4,418,068. This compound is a selective estrogen receptor modulator, useful for alleviating an estrogen-dependent pathological condition of an endocrine target organ. United States Patent No. 5,393,763 described methods for the treatment of bone loss using this compound.

An improved process for the synthesis of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-aminoethoxy)benzoyl]benzo[b]thiophenes was described in U.S. Patent No. 4,380,635. These compounds were prepared by Friedel-Crafts acylation, using aluminum chloride as the catalyst, of a di-O-methyl-protected benzo[b]thiophene. The intermediate acylation product was demethylated by treating the acylation reaction mixture with a sulfur compound, such as methanethiol, ethanethiol, diethyl sulfide, and methionine. The product of this reaction generally contains aluminum salts and various thioester by-products, which are difficult to remove from the benzothiophene. Also, the product has an unpleasant residual thiol or sulfide odor.


Boron halides, such as boron trichloride and boron tribromide, are useful for the cleavage of arylmethyl ethers. See Baht and Kulkarni, *Synthesis*, 249-282 (1983). Boron tribromide has previously been used to cleave arylmethyl ethers in benzothiophene compounds. See German Patent No. DE 4117512 A1.

- 3 -

The processes described above are not suitable for a large-scale synthetic process for preparing 2-aryl-6-hydroxy-3-[4-(2-aminoethoxy)benzoyl]benzo[b]thiophenes. A preferred process would use simple phenolic protecting groups, (such as methyl ethers), readily available starting materials, Friedel-Crafts acylation catalysts that are easily removed and do not present an environmental or health hazard upon disposal, a single reaction vessel, and provide the product in a form that is readily isolated. The process of the present invention fulfills all of these requirements.

Summary of the Invention

The present invention is directed to efficient syntheses of 2-aryl-6-hydroxy-3-[4-(2-aminoethoxy)benzoyl]benzo[b]thiophenes which comprises acylating an aminoalkyl phenyl ether with a suitably-protected benzo[b]thiophene, and dealkylating the protected phenolic group(s) to provide the desired product. In accordance with the preferred aspect of the present invention, the acylation and dealkylation steps are performed successively in a single reaction vessel. More specifically, the present invention is directed to a process for preparing a crystalline solvate of a compound of the formula



wherein:

R^1 is hydrogen or hydroxyl;


R^2 and R^3 are independently C_1 - C_4 alkyl, or R^2 and R^3 together with the adjacent nitrogen atom form a heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, hexamethyleneimino, and morpholino; and

- 4 -

HX is HCl or HBr;
which comprises the steps of:

(a) acylating a compound of the formula


5



wherein HX, R², and R³ are as defined above,

10

with an acylating agent of the formula



wherein:

15

R⁴ is hydrogen or C₁-C₄ alkoxy,

R⁵ is C₁-C₄ alkyl, and

R⁶ is chloro, bromo, or hydroxyl,

in the presence of BX'₃, wherein X' is chloro or bromo;

20


(b) dealkylating one or more phenolic groups by
reacting with additional BX'₃, wherein X' is as defined
above; and

(c) isolating the crystalline solvate.

25

A second aspect of the present invention is directed to
a process for preparing a compound of the formula

- 5 -



IV


or the hydrochloride or hydrobromide salt thereof,
 wherein:

R^4 is hydrogen or C_1 - C_4 alkoxy,

R^5 is C_1 - C_4 alkyl, and

R^2 and R^3 are independently C_1 - C_4 alkyl, or R^2 and R^3 together with the adjacent nitrogen atom form a heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, hexamethyleneimino, and morpholino;

which comprises acylating a compound of the formula



III


wherein:

R^2 and R^3 are independently C_1 - C_4 alkyl, or R^2 and R^3 together with the adjacent nitrogen atom form a heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, hexamethyleneimino, and morpholino; and

HX is HCl or HBr;

with an acylating agent of the formula

- 6 -



II

wherein:

R⁴ is hydrogen or C₁-C₄ alkoxy,

5 R⁵ is C₁-C₄ alkyl, and

R⁶ is chloro, bromo, or hydroxyl;

in the presence of BX'₃, wherein X' is chloro or bromo.

10 **Detailed Description of the Invention**

In the above formula, the term "C₁-C₄ alkyl" represents a straight alkyl chain having from 1 to 4 carbon atoms. Typical C₁-C₄ alkyl groups include methyl, ethyl, *n*-propyl, and *n*-butyl. The term "C₁-C₄ alkoxy" represents groups such
15 as methoxy, ethoxy, *n*-propoxy, and *n*-butoxy. The preferred C₁-C₄ alkoxy group is methoxy.

The term "molar equivalents", as used herein, refers to the number of moles of the boron trihalide reagent in relation to the number of moles of the starting
20 benzothiophene compound. For example, three millimoles of boron trichloride reacted with one millimole of the benzothiophene compound would represent three molar equivalents of boron trichloride.

The term "solvate" represents an aggregate that
25 comprises one or more molecules of the solute, such as a formula I compound, with a molecule of solvent. Representative solvates are formed with methylene chloride, 1,2-dichloroethane, chloroform, and 1,2,3-trichloropropane.

The process of the present invention is useful for the
30 synthesis of a series of compounds having antiestrogenic and antiandrogenic activity. See U.S. Patent Nos. 4,418,068, 4,133,814, and 5,393,763. Representative Formula I

- 7 -

compounds, the products of the processes of this invention, include the following compounds: 6-hydroxy-2-phenyl-3-[4-(2-dimethylaminoethoxy)benzoyl]benzo[b]thiophene, 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-dimethylaminoethoxy)benzoyl]-benzo[b]thiophene, 6-hydroxy-2-phenyl-3-[4-(2-diethylaminoethoxy)benzoyl]benzo[b]thiophene, 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-diethylaminoethoxy)benzoyl]-benzo[b]thiophene, 6-hydroxy-2-phenyl-3-[4-(2-diisopropylaminoethoxy)benzoyl]benzo[b]thiophene, 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-diisopropylaminoethoxy)benzoyl]-benzo[b]thiophene, 6-hydroxy-2-phenyl-3-[4-(2-di-n-butylaminoethoxy)benzoyl]benzo[b]thiophene, 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-di-n-butylaminoethoxy)benzoyl]-benzo[b]thiophene, 6-hydroxy-2-phenyl-3-[4-(2-pyrrolidinoethoxy)benzoyl]benzo[b]thiophene, 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-pyrrolidinoethoxy)benzoyl]-benzo[b]thiophene, 6-hydroxy-2-phenyl-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene, 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]-benzo[b]thiophene, 6-hydroxy-2-phenyl-3-[4-(2-hexamethyleneiminoethoxy)benzoyl]benzo[b]thiophene, 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-hexamethyleneiminoethoxy)benzoyl]benzo[b]thiophene, 6-hydroxy-2-phenyl-3-[4-(2-morpholinoethoxy)benzoyl]benzo[b]thiophene, 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-morpholinoethoxy)benzoyl]-benzo[b]thiophene.

The preferred products of the claimed processes are the Formula I compounds wherein R¹ is hydroxyl, and R² and R³ together with the adjacent nitrogen atom form a pyrrolidino, piperidino, or hexamethyleneimino group. Representative products from this preferred group include 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-pyrrolidinoethoxy)benzoyl]benzo[b]thiophene, 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene, and 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-hexamethyleneiminoethoxy)benzoyl]benzo[b]thiophene. More preferably, the products of the present invention are the Formula I compounds wherein R² and R³

- 8 -

together with the adjacent nitrogen atom form a pyrrolidino or piperidino group. Representative products from this more preferred group include 6-hydroxy-2-(4-hydroxyphenyl)-3-(4-(2-pyrrolidinoethoxy)benzoyl)benzo[b]thiophene and 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene. Most preferably, the product of the present invention is the Formula I compound wherein R¹ is hydroxyl, and R² and R³ together with the adjacent nitrogen atom form a piperidino group. This most preferred product is 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene.

The present invention has several advantages over the prior art processes described above. The processes of the present invention use boron tribromide or boron trichloride as the acylation catalyst in place of aluminum chloride. Aluminum chloride is difficult to handle, especially on a commercial scale. Also, a large amount of aluminum chloride, typically six equivalents, is required for acylation and dealkylation. Aluminum chloride produces a large amount of aluminum by-products, which are insoluble in the work-up solvents and difficult to remove from the pharmaceutically active 2-aryl-6-hydroxy-3-[4-(2-aminoethoxy)benzoyl]benzo[b]thiophenes. The aluminum chloride-catalyzed reactions are generally a heterogeneous mixture. The processes of the present invention are homogeneous, and the boron by-products are soluble in the work-up solvents. Further, the aluminum chloride-catalyzed dealkylation required the addition of a mercaptan or a sulfide for cleavage of the alkyl aryl ethers producing dialkyl sulfides, which exhibit offensive odors. These mercaptans or sulfides are removable by recrystallization; however, this produces a recrystallization solvent with the odorous impurities. The processes of the present invention eliminate the use of aluminum and the use of odorous mercaptans and sulfides.

Typically, the art processes produced a high quantity of related substances and high levels of residual aluminum salts in the final product. Representative related substances


- 9 -

include 6-hydroxy-2-(4-methoxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]-thiophene, 2-(4-hydroxyphenyl)-6-methoxy-3-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene, 6-hydroxy-3-(4-hydroxybenzoyl)-2-(4-hydroxyphenyl)benzo[b]thiophene, propyl 4-(2-piperidinoethoxy)thiobenzoate, methyl 4-(2-piperidinoethoxy)benzoate, 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]-5-[4-(2-piperidinoethoxy)benzoyl]benzo[b]-thiophene, and 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]-7-[4-(2-piperidinoethoxy)benzoyl]benzo[b]thiophene. In the process of the present invention, the boron by-products are easily removed from the final product. Also, the present process avoids the disposal of aluminum waste. When the reaction is carried out in 1,2-dichloroethane, the reactions are homogeneous allowing the use of higher concentrations, and produce crystalline solvates that are readily isolated.

The Formula II and III compounds, the starting materials for the present invention, are prepared using standard synthetic organic methods. The Formula II starting compound can be readily obtained by a synthesis which is exemplified below and outlined in Scheme I.

- 10 -

Scheme I



II

5

The Formula II compounds, wherein R^4 , R^5 , and R^6 are as defined above, can be prepared by first reacting a 3-alkoxybenzenethiol with a phenacyl or 4'-alkoxyphenacyl bromide in the presence of a strong base. Suitable bases for this transformation include, but are not limited to, potassium hydroxide and sodium hydroxide. The reaction is typically carried out in ethanol or a mixture of water and ethanol at a temperature of about 0°C to about 50°C .

10

The next step is cyclization of the arylphenacylsulfide. The cyclization is conveniently carried out by heating the arylphenacylsulfide in polyphosphoric acid. The cyclization is typically carried out at a temperature of about 80°C to about 120°C , preferably between 85°C and 90°C . The

15

SUBSTITUTE SHEET (RULE 26)

- 11 -

intermediate benzothiophene is typically purified by recrystallization. For example, when R⁴ is methoxy and R⁵ is methyl, the intermediate benzothiophene compound may be recrystallized from ethyl acetate.

5 The intermediate benzothiophene compound is converted to a Formula II compound by a sequence of steps comprising halogenation, lithiation, and carboxylation. First, the benzothiophene intermediate is converted to the corresponding
10 3-bromo analog by reaction with bromine in a halogenated hydrocarbon solvent. Suitable halogenated solvents for this reaction include carbon tetrachloride, chloroform, and methylene chloride; preferably a mixture of carbon
15 tetrachloride and chloroform. This transformation is carried out at a temperature of about 25°C to about 55°C. The intermediate 3-bromo benzothiophene compound is isolated using standard techniques, such as by recrystallization.

 The 3-bromo intermediate is lithiated and carboxylated to prepare the Formula II. The 3-bromo benzothiophene compound is reacted with an alkyl lithium, such as *n*-butyl
20 lithium in a dry, polar organic solvent to produce the lithiated compound. Suitable solvents for this reaction include anhydrous diethyl ether, anhydrous tetrahydrofuran, and anhydrous dimethoxyethane. This reaction is typically run at the temperature of about -78°C to about -50°C. The
25 intermediate 3-lithiated benzothiophene compound is treated with carbon dioxide, either solid or gaseous, to produce the Formula II compound wherein R⁶ is OH. This transformation is conveniently carried out in the same solvent as the lithiation reaction. The acid is typically isolated by
30 acidification of the reaction mixture followed by recrystallization. For example, when R⁴ is methoxy, R⁵ is methyl, and R⁶ is hydroxy, the Formula II compound can be recrystallized from absolute ethanol.


 The Formula II compounds, wherein R⁶ is chloro or bromo,
35 are prepared by halogenating the Formula II compounds wherein R⁶ is hydroxyl. Suitable halogenating agents include oxalyl chloride, thionyl chloride, thionyl bromide, phosphorous

- 12 -

tribromide, triphosgene, and phosgene. Preferably, R^6 is chloro. Suitable solvents for this reaction include methylene chloride, 1,2-dichlorobenzene, chlorobenzene, and 1,2-dichloroethane. Preferably, the halogenation reaction is carried out in the same solvent as the subsequent acylation reaction. A catalytic amount of dimethylformamide, from about 0.05 to about 0.25 equivalents, is added to the chlorination reaction. When the reaction is carried out in 1,2-dichloroethane, the reaction is complete after about two to five hours at about 47°C. Preferably, the chlorination reaction and acylation reaction are carried out successively in the same reaction vessel.

The aminoalkyl phenyl ether for the present process, a Formula III compound, can be prepared as shown in Scheme II, wherein the variables R^2 , R^3 , and HX are as defined above.

Scheme II




Generally, a phenol is alkylated with a chloroethylamine in the presence of an inorganic base and isolated as the hydrochloride or hydrobromide salt to produce the Formula III compounds. Examples of chloroethylamines that are useful for preparing the Formula I compounds are 1-(2-chloroethyl)piperidine, 4-(2-chloroethyl)morpholine, and 1-(2-chloroethyl)pyrrolidine. Suitable inorganic bases for this alkylation include potassium carbonate and sodium carbonate. Suitable solvents for this alkylation are non-reactive polar

- 13 -

organic solvents such as methyl ethyl ketone and dimethylformamide.

The 2-aryl-6-hydroxy-3-[4-(2-aminoethoxy)benzoyl[b]-thiophenes can be prepared by acylation and subsequent dealkylation of the phenolic groups in two distinct steps, or sequentially in a "one-pot" reaction. The step-wise synthesis is described in the following paragraphs. The acylated benzothiophene intermediate, a Formula IV compound, is prepared as shown in Scheme III, wherein R^2 , R^3 , R^4 , R^5 , R^6 , and HX are as defined above.

Scheme III




Generally, benzothiophene intermediate II is reacted with a Formula III compound, using boron trichloride or boron tribromide as the acylation catalyst. The reaction is carried out in an organic solvent, such as chlorobenzene, methylene chloride, 1,2-dichloroethane, 1,2-dichlorobenzene, bromobenzene, chloroform, 1,1,2,2-tetrachloroethane, 1,2,3-trichloropropane, and fluorobenzene. Preferably, the acylation is carried out in methylene chloride, chlorobenzene, or 1,2-dichloroethane. Most preferably, the acylation step is carried out in methylene chloride. Because

- 14 -

boron tribromide is more preferred for dealkylation of phenolic ethers, the preferred boron trihalide for catalyzing acylation is boron trichloride. For boron trichloride-catalyzed reactions in methylene chloride, the acylation reaction can be performed at room temperature, with minimal dealkylation of the Formula III and IV compounds. In other solvents, the acylation reaction is carried out at lower temperatures, such as -10°C to 10°C , to minimize the amount of dealkylation of the reaction starting material and product. When R^6 is chloro, at least 2 molar equivalents of the boron trihalide reagent are required for acylation. When the 3-benzoic acid is used as an acylating agent ($\text{R}^6 = \text{OH}$), five equivalents of the boron trihalide are typically used. The Formula IV compound may be isolated as the hydrochloride or hydrobromide salt, or as the free base.

In the step-wise process, the acylated intermediate (Formula IV compound) is dealkylated to produce the Formula I compound as shown in Scheme IV, wherein R^1 , R^2 , R^3 , R^4 , R^5 , and HX are as defined above.

Scheme IV



The Formula I compound can be produced by reacting the hydrochloride or hydrobromide salt of the Formula IV compound


- 15 -

with boron tribromide or boron trichloride. The preferred boron trihalide for dealkylation is boron tribromide. This dealkylation reaction can be carried out in a variety of organic solvents, such as methylene chloride, chlorobenzene, 1,2-dichloroethane, chloroform, 1,1,2,2-tetrachloroethane, 1,2,3-trichloropropane, 1,2-dichlorobenzene, and fluorobenzene. The preferred solvent is 1,2-dichloroethane. When the acid addition salt is used as a starting material, the amount of by-product resulting from dealkylation of the aminoethyl group is minimized. When methylene chloride is used as the solvent and the boron reagent is boron trichloride, the reaction is generally carried out at a temperature of about 55°C to about 75°C, producing the Formula I compound with no detectable cleavage of the aminoethyl group. In other solvents, such as chloroform, 1,2-dichloroethane, chlorobenzene, 1,2-dichlorobenzene, and fluorobenzene, the dealkylation occurs readily at ambient temperatures. For example, when 1,2-dichloroethane is the solvent, the reaction is generally carried out at 25°C to 35°C with no detectable cleavage of the aminoethyl group. At least four equivalents of the boron trihalide reagent are typically used for complete reaction within a reasonable time.

Preferably, the Formula I compounds are prepared by a "one-pot" synthesis from the Formula II and III compounds as shown in Scheme V, wherein R¹, R², R³, R⁴, R⁵, R⁶, and HX are as defined above.

- 16 -

Scheme V



The benzothiophene Formula II compound is reacted with the Formula III compound in the presence of boron trichloride or boron tribromide; boron trichloride is preferred for the "one-pot" process. The reaction can be carried out in a variety of organic solvents, such as chloroform, methylene chloride, 1,2-dichloroethane, 1,2,3-trichloropropane, 1,1,2,2-tetrachloroethane, 1,2-dichlorobenzene, chlorobenzene, and fluorobenzene. The preferred solvent for this synthesis is 1,2-dichloroethane. The reaction is carried out at a temperature of about -10°C to about 25°C, preferably at 0°C. The reaction is best carried out at a concentration of the benzothiophene Formula II compound of about 0.2 M to about 1.0 M. Preferably, two to five molar equivalents of boron trichloride are added to the reaction mixture, most preferably three molar equivalents. The acylation reaction is generally complete after about two hours to about eight hours.

The acylated benzothiophene, the Formula IV compound, is converted to a Formula I compound without isolation. This conversion is performed by adding additional boron trihalide and heating the reaction mixture. Preferably, two to five molar equivalents of boron trichloride are added to the reaction mixture for dealkylation, most preferably three

- 17 -

molar equivalents. This reaction is carried out at a temperature of about 25°C to about 40°C, preferably at 35°C. The reaction is generally complete after about 4 to 48 hours.

5 The acylation/dealkylation reaction is quenched with an alcohol or a mixture of alcohols. Suitable alcohols for use in quenching the reaction include methanol, ethanol, and isopropanol. Preferably, the acylation/dealkylation reaction mixture is added to a 95:5 mixture of ethanol and methanol (3A ethanol). The 3A ethanol can be at room temperature or
10 heated to reflux, preferably at reflux. When the quench is performed in this manner, the Formula I compound conveniently crystallizes from the resulting alcoholic mixture. Generally, 1.25 - 3.75 mL of alcohol per millimole of the benzothiophene starting material are used.

15 The crystalline product of this "one-pot" process, when BCl_3 is used, is isolated as the solvate of the hydrochloride salt. These crystalline solvates are obtained under a variety of conditions. The preparation of a solvate of the Formula I compound, wherein R^1 is hydroxyl, HX is HCl , and R^2 and R^3 together with the adjacent nitrogen atom form a
20 piperidino group, was described previously. Jones et al., *J. Med. Chem.*, **27**, 1057 (1984). Generally, the form of the product of the present process is determined by choice of acylation/dealkylation solvent, boron trihalide, and work-up
25 conditions.

A particularly useful solvate of the formula I compound is the 1,2-dichloroethane solvate. This solvate is prepared by carrying out the "one-pot" acylation/dealkylation process in 1,2-dichloroethane. When R^1 is hydroxyl, R^2 and R^3
30 together with the adjacent nitrogen form a piperidino group, and HX is HCl , the 1,2-dichloroethane solvate can exist in two distinct forms. One crystalline solvate form, termed crystal form I, is prepared by quenching the boron trichloride-catalyzed acylation/ dealkylation reaction with
35 ethanol. Preferably, a mixture of ethanol and methanol (95:5) is used in the preparation of this crystal form.

A second crystalline solvated form is termed crystal

- 18 -

form II. This particular form is prepared by the boron trichloride-catalyzed acylation/dealkylation process using methylene chloride or chloroform as the solvent.

The following examples further illustrate the processes of the present invention. The examples are not intended to be limiting to the scope of the invention in any respect, and should not be so construed. All experiments were run under a positive pressure of dry nitrogen. All solvents and reagents were used as obtained. The percentages are generally calculated on a weight (w/w) basis; except for HPLC solvents which are calculated on a volume (v/v) basis. Proton nuclear magnetic resonance (^1H NMR) spectra were obtained on a Bruker AC-300 FTNMR spectrometer at 300.135 MHz. Melting points were measured on a Mel-Temp II apparatus (Laboratory Devices, USA), and are reported uncorrected.

The reactions were generally monitored for completion using high performance liquid chromatography (HPLC) or thin-layer chromatography (TLC). The acylation, dealkylation, or acylation/dealkylation reactions were monitored for completion using high performance liquid chromatography (HPLC). A sample of the reaction mixture was assayed using a Zorbax RX-C8 column (25 cm x 4.6 mm ID, 5 μ particle), eluting with a gradient as shown below:

GRADIENT SOLVENT SYSTEM

Time (min.)	A (%)	B (%)
0	70	30
12	70	30
14	25	75
16	70	30
25	70	30

A: 0.075 phosphate (pH=2.0)

B: acetonitrile

The reaction mixture was analyzed by diluting a 0.1 mL to 0.2 mL sample to 50 mL with a 60:40 mixture of A/B.

Preparation 1**6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophene**

5 A solution of 3-methoxybenzenethiol (100 grams) and
potassium hydroxide (39.1 grams) in water (300 mL) was added
to denatured ethanol (750 mL), and the resulting mixture
cooled to about 0°C. The cold mixture was treated with 4'-
10 methoxyphenacyl bromide (164 grams) in several small
portions. Upon complete addition, the mixture was cooled for
an additional ten minutes, then allowed to warm to room
temperature. After three hours, the mixture was concentrated
in vacuo, and the residue treated with water (200 mL). The
15 resulting mixture was treated with ethyl acetate, and the
phases were separated. The organic phase was washed with
water (2x), sodium bicarbonate solution (2x), and sodium
chloride solution (2x). The organic phase was then dried
over magnesium sulfate, filtered, and evaporated to dryness
20 in vacuo to give 202 grams of α -(3-methoxyphenylthio)-4-
methoxyacetophenone. This crude product was crystallized
from methanol and washed with hexane to give 158 grams.
Melting point 53°C.

 Polyphosphoric acid (930 grams) was heated to 85°C
and treated with the intermediate product from above
25 (124 grams) in small portions over 30 minutes. Upon complete
addition, the resulting mixture was stirred at 90°C. After
an additional 45 minutes, the reaction mixture was allowed to
cool to room temperature. This mixture was treated with
crushed ice while the mixture was cooled in an ice bath. The
30 resulting mixture was treated with water (100 mL) producing a
light pink precipitate. The precipitate was isolated by
filtration, washed with water and methanol, and dried in
vacuo at 40°C to give 119 grams of 6-methoxy-2-(4-
methoxyphenyl)benzo[b]thiophene. This crude product was
35 slurried in hot methanol, filtered, and washed with cold
methanol. The resulting solid material was recrystallized
from ethyl acetate (4 liters), filtered, washed with hexane,

- 20 -

and dried in vacuo to 68 grams of the title compound.
Melting point 187-190.5°C.

Preparation 2

5 3-bromo-6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophene

 A mixture of the compound prepared as described in
Preparation 1 (10.0 g) and chloroform (400 mL) was heated on
a steambath. Upon complete dissolution, the chloroform
10 solution was treated with a solution of bromine (5.9 g) in
carbon tetrachloride as the chloroform solution cooled from
50°C to 25°C. After an additional half hour at room
temperature, the solution was concentrated in vacuo to give
an oil which crystallized upon standing. This crystalline
15 material was dissolved in hot absolute ethanol (600 mL), and
the volume of the resulting ethanol solution concentrated to
about 400 mL by distillation. Small white needles appeared
which were collected by filtration and dried in vacuo, to
give 11.9 g of the total compound.

20 Analysis calculated for C₁₆H₁₃BrO₂S: C, 55.03; H, 3.75;
Br, 22.88.

 Found: C, 55.30; H, 3.52; Br, 23.00.

Preparation 3

25 6-Methoxy-2-(4-methoxyphenyl)benzo[b]-
 thiophene-3-carboxylic Acid

 A solution of n-butyl lithium in hexane (85 mL, 1.6 M
solution) was added to anhydrous diethyl ether (400 mL), and
30 the resulting solution cooled to about -78°C. The compound
prepared as described in Preparation 2 (40 g) was dissolved
in (150 mL), and the resulting solution was slowly added to
the cold n-butyl lithium over a period of 1-1/2 hr. After an
additional half hour, an additional portion of n-butyl
35 lithium (25 mL) as added. After an additional half hour, the
dry ice/acetone cooling bath was removed, and carbon dioxide
was bubbled through the solution as it slowly warmed to room

- 21 -

temperature. After standing overnight, the resulting mixture was poured onto ice (2 L) and acidified with 1 N hydrochloric acid. The resulting white precipitate was collected by filtration, washed with water, and air dried. This material was added to hot, 1 N sodium hydroxide (150 mL) and the resulting solution was filtered. The filtrate was slowly acidified with concentrated hydrochloric acid. The resulting white precipitate was collected by filtration, washed with water, and air dried. This material was crystallized from absolute ethanol to give 2.715 g of the title compound as small white prisms. The proton nuclear magnetic resonance (¹H NMR) spectrum was consistent with the structure of the title compound.

15

Preparation 4

6-Methoxy-2-(4-methoxyphenyl)benzo[b]-
thiophene-3-carboxylic Acid Chloride

A solution of the compound prepared as described in Preparation 3 (300 mg) and dimethylformamide (2 drops) in 1,2-dichloroethane (5 mL) was cooled to about 0°C. This cold solution was treated with oxalyl chloride (110 µL) over a five-minute period. After stirring overnight at room temperature, the reaction solution was evaporated to dryness in vacuo. The residue was dissolved in 1,2-dichloroethane (2 x 10 mL), and the resulting solution evaporated to dryness. This material was used in the acylation reaction without further purification.

30

Preparation 5

Phenyl 2-Piperidinoethyl Ether Hydrochloride

A mixture of phenol (46.5g), 1-(2-chloroethyl) piperidine (103.5 g), and potassium carbonate (207 g) in dimethylformamide (900 mL) was heated to reflux. After refluxing for two hours, the reaction mixture was allowed to cool to room temperature. This mixture was filtered, and the

- 22 -

solids washed with dimethylformamide (100 mL). The combined filtrates was concentrated in vacuo to a brown oil. This oil was dissolved with ethyl acetate (400 mL), and the resulting solution was washed with water (2 x 200 mL) and saturated brine (2 x 200 mL). The ethyl acetate solution was dried over magnesium sulfate, filtered, and concentrated in vacuo to a brown oil. This oil was dissolved in methanol (100 mL), and the resulting solution acidified with 3% methanolic hydrochloric acid (prepared from acetyl chloride and methanol, 500 mL). The resulting solution was evaporated to dryness in vacuo. The residue (74 g) was crystallized from i-propanol (800 mL) and ethyl acetate (500 mL) to give 59.6 g of the title compound as an off-white crystalline solid. Melting point 179-180°C.

Example 1

6-Hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)-benzoyl]benzo[b]thiophene Hydrochloride
1,2-Dichloroethane Solvate

A solution of the acid chloride prepared as described in Preparation 4 (302 mg) in 1,2-dichloroethane (4 mL) is treated with the compound prepared as described in Preparation 5 (320 g). The resulting solution was cooled to about 0°C and treated with boron trichloride (1.2 mL, 2.35 M solution). The 2.35 M solution of boron trichloride in 1,2-dichloroethane is prepared by condensing boron trichloride (2 mL) in a cold graduated cylinder (dry ice/acetone bath) and adding 1,2-dichloroethane at 0°C to a total volume of 10 mL. The reaction mixture was stirred at 0°C. After six hours, an additional quantity of boron trichloride (1.2 mL, 2.35 M solution) was added to the reaction mixture. The reaction mixture is warmed to 35°C for about 16-20 hours. The resulting reaction mixture was cooled to about 18°C and treated with ethanol (5 mL), allowing the resulting solution to reflux. The resulting solution was seeded with a crystal of the title compound, stirred at room temperature for about

- 23 -

65 hours, and filtered. The filter cake was washed with cold methanol (1x5 mL), and the desired compound dried *in vacuo* at 40°C, to give 220 mg of the title compound. Melting point 250-265°C.

5 ¹HNMR (d₆-DMSO): δ 10.55 (br s, 1H), 9.82 (s, 1H),
9.8 (s, 1H), 7.68 (d, 2H), 7.33 (d, 1H), 7.26 (d, 1H),
7.14 (d, 2H), 6.93 (d, 2H), 6.85 (dd, 1H), 6.68 (d, 2H),
4.43 (m, 2H), 3.93 (s, 1.5H, 1,2-dichlorethane solvate),
3.45 (m, 2H), 3.41 (m, 2H), 2.95 (m, 2H), 1.77 (m, 4H),
10 1.68 (m, 1H), 1.36 (m, 1H).

Preparation 6

6-Hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)-
benzoyl]benzo[b]thiophene Hydrochloride


15

A solution of sodium hydroxide (0.313 g) in methanol (10 mL) was diluted with additional methanol (40 mL) and water (10 mL). This solution was treated with the compound prepared as described in Example 1 (4.0 g). The methanolic
20 phase was treated with 2 N hydrochloric acid (4 mL), producing a crystalline slurry. After one hour, the crystalline product was filtered, washed with methanol (5 mL), and dried at 60° *in vacuo* to give 2.23 g of the title compound.

- 24 -

We claim:

1. A process for preparing a crystalline solvate of a compound of the formula



I

wherein:


R^1 is hydrogen or hydroxyl;

R^2 and R^3 are independently C_1 - C_4 alkyl, or R^2 and R^3 together with the adjacent nitrogen atom form a heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, hexamethyleneimino, and morpholino; and

HX is HCl or HBr;

which comprises the steps of:

(a) acylating a compound of the formula




III

wherein: HX, R^2 , and R^3 are as defined above,

- 25 -

with an acylating agent of the formula



5

wherein:

R⁴ is hydrogen or C₁-C₄ alkoxy;

R⁵ is C₁-C₄ alkyl; and

R⁶ is chloro, bromo, or hydroxyl;

10

in the presence of BX₃', wherein X' is chloro or bromo;

(b) dealkylating one or more phenolic groups of the acylation product of step (a) by reacting with additional BX₃', wherein X' is as defined above; and

(c) isolating the crystalline solvate.

15

2. The process of Claim 1 wherein R⁶ is chloro and HX is HCl.

20

3. The process of Claim 2 wherein R¹ is hydroxyl and R⁴ is C₁-C₄ alkoxy.

25

4. The process of Claim 3 wherein R² and R³ together with the adjacent nitrogen atom form a heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, and hexamethyleneimino.

5. The process of Claim 4 wherein X' is chloro.

30

6. The process of Claim 5 wherein R⁴ is methoxy and R⁵ is methyl.

- 26 -

7. The process of Claim 6 wherein R^2 and R^3 together with the adjacent nitrogen atom form a piperidino group.


8. The process of Claim 7 wherein the acylation is conducted in the presence of 2-5 molar equivalents of BCl_3 .

9. The process of Claim 7 wherein the dealkylation is conducted in presence of 3-10 molar equivalents of BCl_3 .

10. The process of Claim 7 wherein the reaction solvent is one or more solvents selected from the group consisting of chloroform, methylene chloride, 1,2-dichloroethane, 1,2,3-trichloropropane, 1,1,2,2-tetrachloroethane, 1,2-dichlorobenzene, chlorobenzene, and fluorobenzene.

11. The process of Claim 7 wherein the reaction solvent is 1,2-dichloroethane.

12. A process for preparing a compound of the formula



IV

or the hydrochloride or hydrobromide salt thereof, wherein:


R^4 is hydrogen or C_1 - C_4 alkoxy;

R^5 is C_1 - C_4 alkyl; and

R^2 and R^3 are independently C_1 - C_4 alkyl, or R^2 and R^3 together with the adjacent nitrogen atom form a heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, hexamethyleneimino, and morpholino;

which comprises acylating a compound of the formula

- 27 -




wherein:

R² and R³ are independently C₁-C₄ alkyl, or R² and R³ together with the adjacent nitrogen atom form a heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, hexamethyleneimino, and morpholino; and

HX is HCl or HBr;

with an acylating agent of the formula



wherein:

R⁴ and R⁵ are as defined above, and

R⁶ is chloro, bromo, or hydroxyl;

in the presence of BX'₃, wherein X' is chloro or bromo.

13. The process of Claim 12 wherein R⁶ is chloro and HX is HCl.

14. The process of Claim 13 wherein R⁴ is C₁-C₄ alkoxy.

15. The process of Claim 14 wherein R² and R³ together with the adjacent nitrogen atom form a heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, and hexamethyleneimino.

- 28 -

16. The process of Claim 15 wherein X' is chloro.

17. The process of Claim 16 wherein R⁴ is methoxy, and R⁵ is methyl.

5

18. The process of Claim 17 wherein R² and R³ together with the adjacent nitrogen atom form a piperidino group.

10

19. The process of Claim 18 wherein the acylation is conducted in the presence of 2-5 molar equivalents of BCl₃.

15

20. The process of Claim 18 wherein the reaction solvent is one or more solvents selected from the group consisting of chloroform, methylene chloride, chlorobenzene, 1,2-dichloro-ethane, 1,2,3-trichloropropane, 1,1,2,2-tetrachloroethane, 1,2-dichlorobenzene, bromobenzene, and fluorobenzene.


20

21. The process of Claim 18 wherein the reaction solvent is methylene chloride.

22. The process of Claim 21 wherein R⁷ is methyl.

25

23. A process for preparing a crystalline solvate of a compound of the formula



wherein:

R¹ is hydrogen or hydroxyl;

30

R² and R³ are independently C₁-C₄ alkyl, or R² and R³ together with the adjacent nitrogen atom form a hetero-cyclic ring selected from the group consisting of


- 29 -

pyrrolidino, piperidino, hexamethyleneimino, and morpholino; and

HX is HCl or HBr;

which comprises the steps of:

- 5 (a) chlorinating with phosgene, oxallyl chloride, or thionyl chloride a compound of the formula



10 wherein:


R⁴ is hydrogen or C₁-C₄ alkoxy, and

R⁵ is C₁-C₄ alkyl, and

R⁶ is hydroxyl,

to produce a formula II compound wherein R⁶ is chloro;

- 15 (b) acylating a compound of the formula



wherein:

20 HX, R², and R³ are as defined above,

with a compound of formula II, wherein R⁶ is chloro, in the presence of BX'₃, wherein X' is chloro or bromo;

- (c) dealkylating one or more phenolic groups of the acylation product of step (b) by reacting with additional
25 BX'₃, wherein X' is as defined above; and

(d) isolating the crystalline solvate.

24. The process of Claim 23 wherein R¹ is hydroxyl and R⁴ is C₁-C₄ alkoxy.


- 30 -

25. The process of Claim 24 wherein X' is chloro and HX is HCl.

26. The process of Claim 25 wherein R⁴ is methoxy and R⁵ is methyl.

27. The process of Claim 26 wherein R² and R³ together with the adjacent nitrogen atom form a piperidino group.

28. A process for preparing a crystalline solvate of a compound of the formula



I

wherein:


R¹ is hydrogen or hydroxyl;

R² and R³ are independently C₁-C₄ alkyl, or R² and R³ together with the adjacent nitrogen atom form a heterocyclic ring selected from the group consisting of pyrrolidino, piperidino, hexamethyleneimino, and morpholino; and

HX is HCl or HBr;

which comprises the steps of:

(a) chlorinating a compound of the formula



II

- 31 -

wherein:


R⁴ is hydrogen or C₁-C₄ alkoxy, and

R⁵ is C₁-C₄ alkyl, and

5 R⁶ is hydroxyl,

to produce a formula II compound wherein R⁶ is chloro;

(b) acylating a compound of the formula



10

wherein:

HX, R², and R³ are as defined above,

with a compound of formula II, wherein R⁶ is chloro, in the presence of BX'₃, wherein X' is chloro or bromo;

15

(d) dealkylating one or more phenolic groups of the acylation product of step (c) by reacting with additional BX'₃, wherein X' is as defined above; and

(e) isolating the crystalline solvate.

20

29. The process of Claim 28 wherein R¹ is hydroxyl and R⁴ is C₁-C₄ alkoxy.

30. The process of Claim 29 wherein X' is chloro and HX is HCl.

25

31. The process of Claim 30 wherein R⁴ is methoxy and R⁵ is methyl.

30

32. The process of Claim 31 wherein R² and R³ together with the adjacent nitrogen atom form a piperidino group.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/03934

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07D 333/56, 207/02, 409/10, 413/10

US CL : 549/51,57; 548/578; 546/202; 540/596; 544/146

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 549/51,57

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4,133,814 A (JONES ET AL) 09 JANUARY 1979, column 2.	1-32
A	US 4,380,635 A (PETERS) 19 APRIL 1983, columns 11-12.	1-32
A	US 5,223,510 A (GUBIN ET AL) 29 JUNE 1993, columns 13-18.	1-32
A, P	US 5,470,854 A (VON ANGERER ET AL) 28 NOVEMBER 1995, columns 2-5.	1-32
A, P	US 5,472,962 A (KOIZUMI ET AL) 05 DECEMBER 1995, columns 4-8.	1-32

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	
A document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
E earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	*G* document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

11 JUNE 1996

Date of mailing of the international search report

21 JUN 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DEBORAH LAMBKIN

Telephone No. (703) 308-1235